Joseph Bishop, MD
Ophthalmology · Hilton Head Island, SCNPI 1083780415
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,002 of the $135,978 with a category attached, or 66.2%. 23 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 44.2% of the total. Reporting peaked in 2024 at $35,782 and has fallen 74.3% since, to $9,186 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $366.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$60K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$36K
- Johnson & Johnson Surgical Vision, Inc.$24K
- Alcon$9K
- Alcon Research LLC$2K
- Biotissue Holdings Inc.$934
- plus $3K from 17 others
What the payments were for
- Consulting fees$23,73417%
- Speaking & faculty fees$90,00266%
- Travel & lodging$10,3828%
- Food & beverage$11,7429%
- Education$980%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 66 | $60,055 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 62 | $36,451 |
| Johnson & Johnson Surgical Vision, Inc. | 42 | $23,762 |
| Alcon | 60 | $9,450 |
| Alcon Research LLC | 2 | $2,465 |
| Biotissue Holdings Inc. | 14 | $934 |
| Sun Pharmaceutical Industries Inc. | 56 | $869 |
| Mallinckrodt Hospital Products Inc. | 12 | $430 |
| Kala Pharmaceuticals, Inc. | 9 | $326 |
| Oyster Point Pharma, Inc. | 10 | $301 |
| AbbVie(2 entities) | 11 | $294 |
| Novartis | 6 | $121 |
| Ocular Therapeutix, Inc. | 1 | $115 |
| Omeros Corporation | 5 | $86 |
| Tarsus Pharmaceuticals, Inc. | 2 | $59 |
| Eyevance Pharmaceuticals LLC | 3 | $57 |
| Shire North American Group Inc | 3 | $51 |
| Dompe US, Inc. | 2 | $50 |
| Harrow Eye, LLC | 1 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$57,922
- XIIDRA$35,718
- LOTEMAX SM$35,129
- CATALYS SYSTEM$6,863
- ARGOS$4,449
- Catalys Laser System$4,165
- NGENUITY$2,450
- BLINK NUTRITEARS$850
- Clareon$531
- Tecnis IOL$364
- Capella Aberrometer$350
- Centurion$265
- AcrySof IQ PanOptix UV IOL$261
- CEQUA$239
- Tecnis Simplicity$238
- VERITAS Vision System$237
- INVELTYS$233
- AcrySof IQ PanOptix$230
- TYRVAYA$136
- BESIVANCE$130
How this compares
$135,978 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 99 | $76,520 |
| XiidraLifitegrast | 48 | $62,097 |
| TyrvayaVarenicline Tartrate | 62 | $60,980 |
| RestasisCyclosporine | 50 | $51,929 |
| VevyeCyclosporine | 19 | $17,408 |
| CequaCyclosporine | 23 | $16,231 |
| Lotemax SmLoteprednol Etabonate | 51 | $12,618 |
| Cyclosporine | 20 | $11,778 |
| ProlensaBromfenac Sodium | 22 | $7,495 |
| LotemaxLoteprednol Etabonate | 19 | $6,929 |
| Loteprednol Etabonate | 25 | $3,534 |
| Fluorometholone | 25 | $1,557 |
| MoxifloxacinMoxifloxacin Hcl | 78 | $1,482 |
| Prednisolone Acetate | 18 | $739 |
| ValacyclovirValacyclovir Hcl | 16 | $505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $60,055 | $138,617147 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $301 | $60,98062 claims |
| AbbVieRestasis | $294 | $51,92950 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Lotemax, Loteprednol Etabonate | $36,451 | $30,576117 claims |
| Harrow Eye, LLCVevye | $26 | $17,40819 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $869 | $16,23123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Hilton Head Island
- Scott SchultzHilton Head Island$20K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
- David VromanLadson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.